Press Releases

09.14.2024

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

09.14.2024

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

09.11.2024

Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024

08.28.2024

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

08.27.2024

Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare

08.22.2024

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

08.16.2024

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

08.12.2024

Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults

07.30.2024

Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance

07.25.2024

European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B

07.24.2024

Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate

07.11.2024

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron